Skip to main content
SpringerLink
Log in
Book cover

Hypothalamic-Pituitary Diseases pp 61–91Cite as

Physiopathology, Diagnosis, and Treatment of GH Hypersecretion

  • Reference work entry
  • First Online:

  • 1016 Accesses

Part of the book series: Endocrinology ((ENDOCR))

Abstract

Growth hormone excess leads to acromegaly or gigantism, multisystemic diseases associated with great morbidity, and increased mortality when not early recognized and adequately treated. It is caused, in the vast majority of the cases, by a pituitary adenoma (somatotropinoma) that can occur sporadically or associated with some familial diseases. In this chapter the physiopathology, the diagnosis, and the management of GH excess, according to the current knowledge, will be discussed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   299.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Abu Dabrh AM, Mohammed K, Asi N, Farah WH, Wang Z, Farah MH, et al. Surgical interventions and medical treatments in treatment-naive patients with acromegaly: systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(11):4003–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Abu Dabrh A, Asi N, Farah W, Mohammed K, Wang Z, Farah M, et al. Radiotherapy vs. radiosurgery in treating patients with acromegaly: systematic review and meta-analysis. Endocr Pract. 2015;18:1–33.

    Article  Google Scholar 

  • Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab. 2013;98(3):1040–50.

    Article  CAS  PubMed  Google Scholar 

  • Auriemma RS, Pivonello R, Ferreri L, Priscitelli P, Colao A. Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin N Am. 2015;44(1):89–97.

    Article  Google Scholar 

  • Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol. 2003;59(4):492–9.

    Article  CAS  Google Scholar 

  • Barkan A, Bronstein MD, Bruno OD, Cob A, Espinosa-de-los-Monteros AL, Gadelha MR, et al. Management of acromegaly in Latin America: expert panel recommendations. Pituitary. 2010;13(2):168–75.

    Article  PubMed  Google Scholar 

  • Barker FG 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab. 2003;88(10):4709–19.

    Article  CAS  PubMed  Google Scholar 

  • Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev. 1991;12(4):424–49.

    Article  CAS  PubMed  Google Scholar 

  • Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223(4):327–35.

    Article  CAS  PubMed  Google Scholar 

  • Bengtsson D, Schroder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, et al. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab. 2015;100(4):1689–98.

    Article  CAS  PubMed  Google Scholar 

  • Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin N Am. 2008;37(1):101–22.

    Article  CAS  Google Scholar 

  • Bernabeu I, Alvarez-Escola C, Paniagua AE, Lucas T, Pavon I, Cabezas-Agricola JM, et al. Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary. 2013;16(1):101–8.

    Article  CAS  PubMed  Google Scholar 

  • Bevan JS, Newell-Price J, Wass JA, Atkin SL, Bouloux PM, Chapman J, et al. Home administration of lanreotide autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol. 2008;68(3):343–9.

    CAS  Google Scholar 

  • Buchfelder M, Schlaffer SM. Modern imaging of pituitary adenomas. Front Horm Res. 2010;38:109–20.

    Article  PubMed  Google Scholar 

  • Buhk JH, Jung S, Psychogios MN, Goricke S, Hartz S, Schulz-Heise S, et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab. 2010;95(2):552–8.

    Article  CAS  PubMed  Google Scholar 

  • Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab. 2008;93(8):2984–90.

    Article  CAS  PubMed  Google Scholar 

  • Carlsen SM, Svartberg J, Schreiner T, Aanderud S, Johannesen O, Skeie S, et al. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin Endocrinol. 2011;74(6):736–43.

    Article  CAS  Google Scholar 

  • Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab. 2009;94(2):523–7.

    Article  CAS  PubMed  Google Scholar 

  • Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prevost G, et al. Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282–90.

    Article  CAS  PubMed  Google Scholar 

  • Casagrande A, Bronstein MD, Jallad RS, Moraes AB, Elias PC, Castro M, et al. Long-term remission of acromegaly after octreotide withdrawal is an uncommon and frequently unsustainable event. Neuroendocrinology. 2017;104(3):273–9.

    Google Scholar 

  • Casini AF, Araujo PB, Fontes R, Xavier SS, Gadelha MR. Cardiac morphology and performance alterations and analysis of determinant factors of left ventricular hypertrophy in 40 patients with acromegaly. Arq Bras Endocrinol Metabol. 2006;50(1):82–90.

    Article  PubMed  Google Scholar 

  • Casini AF, Neto LV, Fontes R, Franca RF, Xavier SS, Gadelha MR. Aortic root ectasia in patients with acromegaly: experience at a single center. Clin Endocrinol. 2011;75(4):495–500.

    Article  Google Scholar 

  • Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, et al. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab. 2012;97(4):E663–70.

    Article  CAS  PubMed  Google Scholar 

  • Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J. Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab. 2009;23(5):555–74.

    Article  CAS  PubMed  Google Scholar 

  • Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab. 2003;88(7):3196–201.

    Article  CAS  PubMed  Google Scholar 

  • Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–52.

    Article  CAS  PubMed  Google Scholar 

  • Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol. 2007;157(5):579–87.

    Article  CAS  PubMed  Google Scholar 

  • Colao A, Cappabianca P, Caron P, De Menis E, Farrall AJ, Gadelha MR, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf). 2009a;70(5):757–68.

    Article  Google Scholar 

  • Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab. 2009b;94(10):3746–56.

    Article  CAS  PubMed  Google Scholar 

  • Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary. 2016;19(3):235–47.

    Google Scholar 

  • Concolino P, Costella A, Capoluongo E. Multiple endocrine neoplasia type 1 (MEN1): an update of 208 new germline variants reported in the last nine years. Cancer Genet. 2016;209(1–2):36–41.

    Article  PubMed  Google Scholar 

  • Cook DM. Long-term management of prolactinomas – use of long-acting dopamine agonists. Rev Endocr Metab Disord. 2005;6(1):15–21.

    Article  PubMed  Google Scholar 

  • Correa LL, Taboada GF, Van Haute FR, Casini AF, Balarini GA, Vieira Neto L, et al. Evaluation of glucose metabolism in acromegalic patients before and after treatment with octreotide LAR. Arq Bras Endocrinol Metabol. 2008;52(1):55–64.

    Article  PubMed  Google Scholar 

  • Correa R, Salpea P, Stratakis CA. Carney complex: an update. Eur J Endocrinol. 2015;173(4):M85–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege. Belgium J Clin Endocrinol Metab. 2006;91(12):4769–75.

    Article  CAS  PubMed  Google Scholar 

  • Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, Barlier A, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95(11):E373–83.

    Article  PubMed  Google Scholar 

  • Davi MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol. 2008;159(5):533–40.

    Article  CAS  PubMed  Google Scholar 

  • Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93(1):61–7.

    Article  CAS  PubMed  Google Scholar 

  • Denes J, Swords F, Rattenberry E, Stals K, Owens M, Cranston T, et al. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab. 2015;100(3):E531–41.

    Article  CAS  PubMed  Google Scholar 

  • dos Santos Silva CM, Gottlieb I, Volschan ICM, Kasuki L, Warszawski L, Lima GA, et al. Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort. J Clin Endocrinol Metab. 2015a;100(12):4447–55.

    Article  PubMed  CAS  Google Scholar 

  • Dos Santos Silva CM, Lima GA, Volschan IC, Gottlieb I, Kasuki L, Neto LV, et al. Low risk of coronary artery disease in patients with acromegaly. Endocrine. 2015b;50(3):749–55.

    Article  PubMed  CAS  Google Scholar 

  • Fathalla H, Cusimano MD, Di Ieva A, Lee J, Alsharif O, Goguen J, et al. Endoscopic versus microscopic approach for surgical treatment of acromegaly. Neurosurg Rev. 2015;38(3):541–8.

    Article  PubMed  Google Scholar 

  • Fatti LM, Scacchi M, Lavezzi E, Pecori Giraldi F, De Martin M, Toja P, et al. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol. 2006;65(5):626–30.

    Article  CAS  Google Scholar 

  • Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377–82.

    Google Scholar 

  • Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M, Teti C, et al. The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol. 2009;42(5):361–70.

    Article  CAS  PubMed  Google Scholar 

  • Flitsch J, Ludecke DK, Stahnke N, Wiebel J, Saeger W. Transsphenoidal surgery for pituitary gigantism and galactorrhea in a 3.5 year old child. Pituitary. 2000;2(4):261–7.

    Article  CAS  PubMed  Google Scholar 

  • Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol. 2012;76(1):96–102.

    Article  CAS  Google Scholar 

  • Fougner SL, Bollerslev J, Svartberg J, Oksnes M, Cooper J, Carlsen SM. Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. Eur J Endocrinol. 2014;171(2):229–35.

    Article  CAS  PubMed  Google Scholar 

  • Franck SE, Van der Lely AJ, Delhanty PJ, Jorgensen JO, Neggers SJ. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the growth hormone receptor deletion of exon 3. Eur J Endocrinol. 2015;173(5):553–61.

    Article  CAS  PubMed  Google Scholar 

  • Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90(8):4465–73.

    Article  CAS  PubMed  Google Scholar 

  • Gadelha MR. A paradigm shift in the medical treatment of acromegaly: from a ‘trial and error’ to a personalized therapeutic decision-making process. Clin Endocrinol. 2015;83(1):1–2.

    Article  Google Scholar 

  • Gadelha MR, Une KN, Rohde K, Vaisman M, Kineman RD, Frohman LA. Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J Clin Endocrinol Metab. 2000;85(2):707–14.

    CAS  PubMed  Google Scholar 

  • Gadelha MR, Kasuki L, Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab. 2013a;24(5):238–46.

    Article  CAS  PubMed  Google Scholar 

  • Gadelha MR, Trivellin G, Hernandez Ramirez LC, Korbonits M. Genetics of pituitary adenomas. Front Horm Res. 2013b;41:111–40.

    Article  CAS  PubMed  Google Scholar 

  • Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–84.

    Article  CAS  PubMed  Google Scholar 

  • Gadelha MR, Kasuki L, Korbonits M. The genetic background of acromegaly. Pituitary. 2017a;20(1):10–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. 2017b;20(1):100–8.

    Article  CAS  PubMed  Google Scholar 

  • Garby L, Caron P, Claustrat F, Chanson P, Tabarin A, Rohmer V, et al. Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases. J Clin Endocrinol Metab. 2012;97(6):2093–104.

    Article  CAS  PubMed  Google Scholar 

  • Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol. 2009;161(2):331–8.

    Article  CAS  PubMed  Google Scholar 

  • Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141–8.

    Article  CAS  PubMed  Google Scholar 

  • Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012;7(5):e36411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243–8.

    Article  CAS  PubMed  Google Scholar 

  • Giustina A, Arnaldi G, Bogazzi F, Cannavo S, Colao A, De Marinis L, et al. Pegvisomant in acromegaly: an update. J Endocrinol Invest. 2017;40(6):577–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gunawardane K, Krarup Hansen T, Sandahl Christiansen J, Lunde Jorgensen JO. Normal physiology of growth hormone in adults. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth (MA); 2000.

    Google Scholar 

  • Hatipoglu E, Bozcan S, Kadioglu P. Discontinuation of somatostatin analogs while acromegaly is in long-term remission. Pituitary. 2015;18(4):554–60.

    Article  CAS  PubMed  Google Scholar 

  • Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446–53.

    Article  CAS  PubMed  Google Scholar 

  • Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab. 1990;71(6):1427–33.

    Article  CAS  PubMed  Google Scholar 

  • Hernandez-Ramirez LC, Gabrovska P, Denes J, Stals K, Trivellin G, Tilley D, et al. Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers. J Clin Endocrinol Metab. 2015;100(9):E1242–54.

    Article  PubMed  PubMed Central  Google Scholar 

  • Higham CE, Thomas JD, Bidlingmaier M, Drake WM, Trainer PJ. Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol. 2009;161(1):21–5.

    Article  CAS  PubMed  Google Scholar 

  • Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab. 2012;97(4):1187–93.

    Article  CAS  PubMed  Google Scholar 

  • Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004;89(4):1577–85.

    Article  CAS  PubMed  Google Scholar 

  • Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89–95.

    Article  CAS  PubMed  Google Scholar 

  • Iacovazzo D, Caswell R, Bunce B, Jose S, Yuan B, Hernandez-Ramirez LC, et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathol Commun. 2016;4(1):56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Jahangiri A, Wagner J, Tran MT, Miller LM, Tom MW, Kunwar S, et al. Factors predicting postoperative hyponatremia and efficacy of hyponatremia management strategies after more than 1000 pituitary operations. J Neurosurg. 2013;119(6):1478–83.

    Article  PubMed  Google Scholar 

  • Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol. 2007;67(2):310–5.

    Article  CAS  Google Scholar 

  • Kasuki L, Vieira Neto L, Gadelha MR. Cabergoline treatment in acromegaly: cons. Endocrine. 2014;46(2):220–5.

    Article  CAS  PubMed  Google Scholar 

  • Kato Y, Murakami Y, Sohmiya M, Nishiki M. Regulation of human growth hormone secretion and its disorders. Intern Med. 2002;41(1):7–13.

    Article  CAS  PubMed  Google Scholar 

  • Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly – 2011 update: executive summary. Endocr Pract. 2011;17(4):636–46.

    Article  PubMed  Google Scholar 

  • Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–51.

    Article  CAS  PubMed  Google Scholar 

  • Kayano K, Takeo M, Morisue S, Yamamoto M, Mizuno Y, Meguro F. A case of human growth hormone (h-GH)-producing adenocarcinoma of the lung. Nippon Kyobu Geka Gakkai Zasshi. 1995;43(4):538–42.

    CAS  PubMed  Google Scholar 

  • Killinger Z, Payer J, Lazurova I, Imrich R, Homerova Z, Kuzma M, et al. Arthropathy in acromegaly. Rheum Dis Clin N Am. 2010;36(4):713–20.

    Article  CAS  Google Scholar 

  • Korbonits M, Storr H, Kumar AV. Familial pituitary adenomas – who should be tested for AIP mutations? Clin Endocrinol. 2012;77(3):351–6.

    Article  CAS  Google Scholar 

  • Kristof RA, Rother M, Neuloh G, Klingmuller D. Incidence, clinical manifestations, and course of water and electrolyte metabolism disturbances following transsphenoidal pituitary adenoma surgery: a prospective observational study. J Neurosurg. 2009;111(3):555–62.

    Article  PubMed  Google Scholar 

  • Kropf LL, Madeira M, Vieira Neto L, Gadelha MR, de Farias ML. Functional evaluation of the joints in acromegalic patients and associated factors. Clin Rheumatol. 2013;32(7):991–8.

    Article  PubMed  Google Scholar 

  • Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol. 2001;54(5):311–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee CC, Vance ML, Xu Z, Yen CP, Schlesinger D, Dodson B, et al. Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab. 2014;99(4):1273–81.

    Article  CAS  PubMed  Google Scholar 

  • Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7(6):518–20.

    Article  PubMed  Google Scholar 

  • Lloyd RV, Kovacs K, Young WF Jr, Farrel WE, Asa SL, Trouillas J, et al. Pituitary tumours: introduction. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. WHO classification of tumours pathology and genetics tumours of endocrine organs. Lyon: IARC Press; 2004. p. 10–3.

    Google Scholar 

  • Lorcy Y, Dejager S, Chanson P, French Octreotide LARG. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary. 2000;3(3):193–7.

    Article  CAS  PubMed  Google Scholar 

  • Losa M, Bogazzi F, Cannavo S, Ceccato F, Curto L, De Marinis L, et al. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. J Neuro-Oncol. 2016;126(3):519–25.

    Article  CAS  Google Scholar 

  • Machado EO, Taboada GF, Neto LV, van Haute FR, Correa LL, Balarini GA, et al. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Hormon IGF Res. 2008;18(5):389–93.

    Article  CAS  Google Scholar 

  • Madeira M, Neto LV, de Lima GA, Moreira RO, de Mendonca LM, Gadelha MR, et al. Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly. Osteoporos Int. 2010;21(12):2019–25.

    Article  CAS  PubMed  Google Scholar 

  • Madeira M, Neto LV, de Paula Paranhos Neto F, Barbosa Lima IC, Carvalho de Mendonca LM, Gadelha MR, et al. Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2013a;98(4):1734–41.

    Article  CAS  PubMed  Google Scholar 

  • Madeira M, Neto LV, Torres CH, de Mendonca LM, Gadelha MR, de Farias ML. Vertebral fracture assessment in acromegaly. J Clin Densitom. 2013b;16(2):238–43.

    Article  PubMed  Google Scholar 

  • Manara R, Maffei P, Citton V, Rizzati S, Bommarito G, Ermani M, et al. Increased rate of intracranial saccular aneurysms in acromegaly: an MR angiography study and review of the literature. J Clin Endocrinol Metab. 2011;96(5):1292–300.

    Article  CAS  PubMed  Google Scholar 

  • Marie P. Sur deux cas d'acromégalie: Hypertrophie singulière non congénitale des extremités supérieures, inférieures et céphaliques. Rev Med. 1886;6:297.

    Google Scholar 

  • Mattar P, Alves Martins MR, Abucham J. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. Neuroendocrinology. 2010;92(2):120–7.

    Article  CAS  PubMed  Google Scholar 

  • McCormack AI, Wass JA, Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Investig. 2011;41(10):1133–48.

    Article  CAS  Google Scholar 

  • Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119(11):3189–202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Melmed S, Ezrin C, Kovacs K, Goodman RS, Frohman LA. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med. 1985;312(1):9–17.

    Article  CAS  PubMed  Google Scholar 

  • Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509–17.

    Article  CAS  PubMed  Google Scholar 

  • Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16(3):294–302.

    Article  CAS  PubMed  Google Scholar 

  • Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol. 2007;66(6):859–68.

    Article  CAS  Google Scholar 

  • Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab. 2014;99(12):4438–46.

    Article  CAS  PubMed  Google Scholar 

  • Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab. 2005;90(2):800–4.

    Article  CAS  PubMed  Google Scholar 

  • Minniti G, Scaringi C, Enrici RM. Radiation techniques for acromegaly. Radiat Oncol. 2011;6:167.

    Article  PubMed  PubMed Central  Google Scholar 

  • Muller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, et al. Ghrelin. Mol Metab. 2015;4(6):437–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Murray PG, Higham CE, Clayton PE. 60 YEARS OF NEUROENDOCRINOLOGY: the hypothalamo-GH axis: the past 60 years. J Endocrinol. 2015;226(2):T123–40.

    Article  CAS  PubMed  Google Scholar 

  • Neggers SJ, van der Lely AJ. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Hormon IGF Res. 2011;21(3):129–33.

    Article  CAS  Google Scholar 

  • Neggers SJ, de Herder WW, Feelders RA, van der Lely AJ. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary. 2011;14(3):253–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Neggers SJ, Franck SE, de Rooij FW, Dallenga AH, Poublon RM, Feelders RA, et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2014;99(10):3644–52.

    Article  CAS  PubMed  Google Scholar 

  • Neggers SJ, Pronin V, Balcere I, Lee MK, Rozhinskaya L, Bronstein MD, et al. Lanreotide autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. Eur J Endocrinol. 2015;173(3):313–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol. 2005;152(3):379–87.

    Article  CAS  PubMed  Google Scholar 

  • Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol. 2008;19(2):82–91.

    Article  PubMed  Google Scholar 

  • Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G, Trainer PJ. Pegvisomant interference in GH assays results in underestimation of GH levels. Eur J Endocrinol. 2007;156(3):315–9.

    Article  CAS  PubMed  Google Scholar 

  • Pendleton C, Adams H, Mathioudakis N, Quinones-Hinojosa A. Sellar door: Harvey Cushing’s entry into the pituitary gland, the unabridged Johns Hopkins experience 1896–1912. World Neurosurg. 2013;79(2):394–403.

    Article  PubMed  Google Scholar 

  • Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, Pena L, Lugo G, Sangiao-Alvarellos S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS One. 2013;8(4):e61523.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ramirez C, Vargas G, Gonzalez B, Grossman A, Rabago J, Sosa E, et al. Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? Eur J Endocrinol. 2012;166(1):21–6.

    Article  CAS  PubMed  Google Scholar 

  • Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol. 2010;72(2):203–8.

    Article  Google Scholar 

  • Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol. 2008;14(22):3484–9.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ronchi CL, Rizzo E, Lania AG, Pivonello R, Grottoli S, Colao A, et al. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol. 2008;158(1):19–25.

    Article  CAS  PubMed  Google Scholar 

  • Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, Lecoq AL, et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer. 2015;22(5):745–57.

    Article  CAS  PubMed  Google Scholar 

  • Salvatori R, Nachtigall LB, Cook DM, Bonert V, Molitch ME, Blethen S, et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary. 2010;13(2):115–22.

    Article  CAS  PubMed  Google Scholar 

  • Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327–35.

    Article  CAS  PubMed  Google Scholar 

  • Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007 Jan 4;356(1):29–38.

    Article  CAS  PubMed  Google Scholar 

  • Schilbach K, Bidlingmaier M. Growth hormone binding protein – physiological and analytical aspects. Best Pract Res Clin Endocrinol Metab. 2015;29(5):671–83.

    Article  CAS  PubMed  Google Scholar 

  • Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane JA Jr. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab. 2013;98(8):3190–8.

    Article  CAS  PubMed  Google Scholar 

  • Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol. 2008;158(3):295–303.

    Article  CAS  PubMed  Google Scholar 

  • Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386(1–2):2–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011.

    Article  CAS  PubMed  Google Scholar 

  • Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171–7.

    Article  CAS  PubMed  Google Scholar 

  • Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014;371(25):2363–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tutuncu Y, Berker D, Isik S, Ozuguz U, Akbaba G, Kucukler FK, et al. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary. 2012;15(3):398–404.

    Article  CAS  PubMed  Google Scholar 

  • Uchoa HB, Lima GA, Correa LL, Vidal AP, Cavallieri SA, Vaisman M, et al. Prevalence of thyroid diseases in patients with acromegaly: experience of a Brazilian center. Arq Bras Endocrinol Metabol. 2013;57(9):685–90.

    Article  PubMed  Google Scholar 

  • van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754–9.

    Article  PubMed  Google Scholar 

  • van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012;97(5):1589–97.

    Article  PubMed  CAS  Google Scholar 

  • van Haute FR, Taboada GF, Correa LL, Lima GA, Fontes R, Riello AP, et al. Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging. Eur J Endocrinol. 2008;158(4):459–65.

    Article  PubMed  CAS  Google Scholar 

  • Vandeva S, Elenkova A, Natchev E, Kirilov G, Tcharaktchiev D, Yaneva M, et al. Treatment outcome results from the Bulgarian Acromegaly Database: adjuvant dopamine agonist therapy is efficient in less than one fifth of non-irradiated patients. Exp Clin Endocrinol Diabetes. 2015;123(1):66–71.

    Article  CAS  PubMed  Google Scholar 

  • Vieira Neto L, Taboada GF, Correa LL, Polo J, Nascimento AF, Chimelli L, et al. Acromegaly secondary to growth hormone-releasing hormone secreted by an incidentally discovered pheochromocytoma. Endocr Pathol. 2007;18(1):46–52.

    Article  CAS  PubMed  Google Scholar 

  • Vieira Neto L, Abucham J, Araujo LA, Boguszewski CL, Bronstein MD, Czepielewski M, et al. Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol. 2011;55(2):91–105.

    Article  PubMed  Google Scholar 

  • Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312(5777):1228–30.

    Article  CAS  PubMed  Google Scholar 

  • Vilar L, Azevedo MF, Naves LA, Casulari LA, Albuquerque JL, Montenegro RM, et al. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary. 2011;14(2):148–56.

    Article  CAS  PubMed  Google Scholar 

  • Vilar L, Fleseriu M, Naves LA, Albuquerque JL, Gadelha PS, dos Santos Faria M, et al. Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial. Endocrine. 2014;46(3):577–84.

    CAS  PubMed  Google Scholar 

  • Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. 2009;64(4):647–55.

    Article  CAS  PubMed  Google Scholar 

  • Volschan I, Kasuki L, Silva CM, Alcantara ML, Saraiva RM, Xavier SS, et al. Two-dimensional speckle tracking echocardiography demonstrates no effect of active acromegaly on left ventricular strain. Pituitary. 2017;20:349–57.

    Article  CAS  PubMed  Google Scholar 

  • Warszawski L, Kasuki L, Sa R, Dos Santos Silva CM, Volschan I, Gottlieb I, et al. Low frequency of cardiac arrhythmias and lack of structural heart disease in medically-naive acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary. 2016;19(6):582–9.

    Article  CAS  PubMed  Google Scholar 

  • Wassenaar MJ, Cazemier M, Biermasz NR, Pereira AM, Roelfsema F, Smit JW, et al. Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study. J Clin Endocrinol Metab. 2010;95(5):2073–9.

    Article  CAS  PubMed  Google Scholar 

  • Wildemberg LE, Gadelha MR. Pasireotide for the treatment of acromegaly. Expert Opin Pharmacother. 2016;17(4):579–88.

    Article  CAS  PubMed  Google Scholar 

  • Wildemberg LE, Neto LV, Costa DF, Nasciuti LE, Takiya CM, Alves LM, et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Investig. 2013;36(1):38–43.

    CAS  Google Scholar 

  • Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356(1):39–46.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroendocrinology Research Center, Hospital Universitário Clementino Fraga Filho of Universidade Federal do Rio de Janeiro (HUCFF/UFRJ), Rio de Janeiro, BJ, Brazil

    Leandro Kasuki, Marília Duarte Dalmolin & Mônica Gadelha

  2. Neuroendocrinology Unit and Molecular Genetics Laboratory, Instituto Estadual do Cérebro Paulo Niemeyer (IECPN), Rio de Janeiro, BJ, Brazil

    Leandro Kasuki & Mônica Gadelha

Authors
  1. Leandro Kasuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marília Duarte Dalmolin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mônica Gadelha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leandro Kasuki .

Editor information

Editors and Affiliations

  1. Faculty of Medicine, Biochemistry and Molecular Biology Department, University of Santiago de Compostela, Santiago de Compostela, Spain

    Felipe F. Casanueva

  2. Department of Medical Sciences, University of Torino, Torino, Italy

    Ezio Ghigo

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Kasuki, L., Dalmolin, M.D., Gadelha, M. (2018). Physiopathology, Diagnosis, and Treatment of GH Hypersecretion. In: Casanueva, F., Ghigo, E. (eds) Hypothalamic-Pituitary Diseases. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-44444-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-44444-4_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44443-7

  • Online ISBN: 978-3-319-44444-4

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation